Drugs / Monovalent Oral Polio Vaccine Type 2 (mOPV2)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01831050 Background | May 2013 → Apr 2014 | poliomyelitis | Fidec Corporation | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Monovalent Oral Polio Vaccine Type 2 (mOPV2) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01831050 ↗ |
| Modality | Vaccine | “monovalent, live attenuated poliomyelitis virus vaccine” NCT01831050 ↗ |
| Route | Oral | “Polio Sabin Mono Two (oral)” NCT01831050 ↗ |